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New diagnostic criteria for multiple sclerosis (MS) were published in 2001 by McDonald and 
colleagues.1 These criteria take account of the clinical features, brain and spinal-cord MRI 
findings, CSF findings, and visual evoked-potential studies. The McDonald criteria define 
rigorous MRI requirements but do not define an optimum CSF test for the diagnosis of MS. 
CSF testing should be optimised, because, in the McDonald criteria, a positive CSF study is 
an essential diagnostic criterion in patients who have objective clinical evidence of only one 
lesion and only a few MRI lesions, and it is a mandatory criterion for the diagnosis of primary 
progressive MS.1 The rationale underpinning the use of CSF testing is the determination of 
whether there is synthesis of immunoglobulin G (IgG) in the CNS compartment (intrathecal 
synthesis). This indicates expansion of B cells in the CNS and is a characteristic feature of 
MS. In the McDonald criteria, a positive CSF study is defined as one showing either 
oligoclonal IgG bands or a high IgG index, which are two different indicators of intrathecal 
IgG synthesis. These indicators differ in sensitivity and specificity, and there are also 
differences in the techniques of CSF analysis. 
 
 
Oligoclonal IgG in the CSF is a diagnostic feature of multiple sclerosis. 
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To assess and recommend the type of CSF analysis that is optimum for a diagnosis of MS, the 
Consortium of Multiple Sclerosis Clinics commissioned a study group that included 
individuals who had considerable expertise in CSF analysis, the diagnosis and management of 
patients with MS, or both. The result is a recently published helpful consensus statement 
recommending a standard of CSF analysis in the diagnosis of MS.2 The consensus group 
recommend that the gold standard should be qualititative assessment of paired CSF and serum 
samples for the detection of oligoclonal IgG bands that are present in the CSF but not the 
serum by use of isoelectric focusing and some form of immunodetection (immunoblotting or 
immunofixation). The recommendation is based on their conclusion that this method is more 
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sensitive and specific than quantitative IgG analytic methods, such as the IgG index. This 
difference results from fundamental differences in the way the two techniques distinguish 
normal from abnormal. In quantitative analysis, each patient is compared with a large 
population and, hence, a wide reference range of blood-derived proteins in CSF, whereas in 
qualitative analysis each patient's CSF IgG pattern is compared with his or her own serum 
sample. 
Freedman and coauthors2 recommend that consideration be given to repeating the lumbar 
puncture and CSF analysis if the clinical suspicion is high and if the CSF results are 
equivocal, negative, or show only a single band.2 They also recommend that other 
components of the CSF analysis, such as the cell count, protein, glucose and lactate 
concentrations, should also be considered in the diagnosis of MS. One area worthy of further 
study is the usefulness of a high CSF leucocyte count and of leucocyte phenotyping in the 
diagnosis of MS. High CSF leucocyte counts, which are indicative of CNS inflammation and 
can occur in the absence of detectable oligoclonal IgG bands, have become undervalued in the 
differentiation of MS from non-inflammatory CNS disorders. 
Whereas the sensitivity for detecting oligoclonal IgG banding with isoelectric focusing and 
immunodetection is high ( 90%) in relapsing-remitting MS, it seems to be substantially 
lower in primary-progressive MS. Furthermore, it is often difficult to be sure about the 
diagnosis of primary-progressive MS unless the CSF shows intrathecal synthesis of IgG, a 
fact recognised by the mandatory requirement of the McDonald criteria for a positive CSF 
study for this diagnosis.1 There have been no large studies with isoelectric focusing and 
immunodetection to compare relapsing-remitting MS and clinically diagnosed primary-
progressive MS, but one small study found a sensitivity of 85% in relapsing-remitting MS and 
only 58% in chronic-progressive MS, although the researchers did not clarify whether the 
progressive group comprised only patients with primary-progressive disease or whether it also 
included those with secondary-progressive MS.3 
A fundamental topic of debate is the pathogenetic significance of the oligoclonal IgG bands in 
the CSF: whether each individual band is monoclonal or not is unknown. However, analysis 
of immunoglobulin heavy-chain variable-region genes has shown monoclonal B-cell 
expansion in the CSF of patients with MS.4 The monoclonal expansion of B cells in the CNS 
in MS and in the target organs of other chronic autoimmune diseases, such as Sjögren's 
syndrome and autoimmune thyroiditis, may be due to infection of these B cells by the 
Epstein-Barr virus, and the infected B cells might produce pathogenic autoantibodies and 
promote survival of autoreactive T cells in the target organ.5 The new consensus statement on 
CSF analysis2 is a step forward in optimising and standardising the diagnosis of MS. 
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